Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peginterferon alfa-2b in CHB with MAFLD (real-world cohort)
ChiCTR2500109436Phase 4Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Sep 2025
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of peginterferon alfa-2b in Chronic Hepatitis B (CHB) and metabolic dysfunction-associated steatotic liver disease (MASLD) (2 arms), sponsored by Peking University People's Hospital. Primary endpoints: HBsAg Clearance Rate and Liver Stiffness Measurement (LSM). Planned start Sep 2025; status: not yet recruiting.
02
Drugs
peginterferon alfa-2b
03
Conditions
Chronic Hepatitis B (CHB)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on ChiCTR2500109436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109436.